Press Releases
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data Collaboration will expand Regeneron’s world-leading genomic and proteomic EHR-linked database ...
TriNetX Unveils Conversational AI Interface and Enhanced API Capabilities
Success achieved in reducing trial costs and timelines drives 2026 platform enhancements designed to democratize clinical research analytics. CAMBRIDGE, Mass., January 22, 2026 — TriNetX, driven by its vision of a connected world where data and intelligence power...
TriNetX Becomes the Most Cited Real-World Data Source in Peer-Reviewed Research
With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top medical journals. CAMBRIDGE Mass., October 15, 2025 — TriNetX, driven by its vision of a connected world where data and...
TriNetX Named Among the Top 25 Healthcare Software Companies of 2025
Recognition by The Healthcare Technology Report underscores TriNetX’s innovation in real-world data, artificial intelligence, and clinical research transformation. CAMBRIDGE Mass., September 25, 2025 — TriNetX, the company behind the world’s broadest federated...
New TriNetX Research Impact Report Illuminates How Real-World Data is Fueling Rare Disease Innovation
Analysis reveals strategic opportunities for pharmaceutical leaders to close treatment gaps and accelerate breakthroughs in underserved rare disease communities. Cambridge, MA, July 31, 2025 — TriNetX, driven by its vision of a connected world where data and...
New TriNetX Survey Reveals Biopharma’s Bold Embrace of Real-World Data and Artificial Intelligence—But Warns of Looming Barriers
Real-world data (RWD), artificial intelligence (AI), and patient-centric trial design lead pharma priorities in 2025, but data compatibility, regulatory hurdles, and security concerns threaten to stall momentum. CAMBRIDGE, MA – July 10, 2025 – As...